Provera (Medroxyprogesterone Acetate): A Comprehensive Overview

Provera, the brand name for medroxyprogesterone acetate (MPA), is a synthetic progestin medication widely used in gynecology and reproductive medicine. It mimics the actions of the natural hormone progesterone, playing a crucial role in regulating the menstrual cycle, treating various hormonal disorders, and serving as a component of hormone replacement therapy (HRT) and contraception. This report provides a concise yet thorough examination of Provera, covering its pharmacology, clinical applications, side effects, contraindications, and current role in modern medicine.

Pharmacology and Mechanism of Action

Medroxyprogesterone acetate is a derivative of progesterone, modified to enhance oral bioavailability and prolong its duration of action. It acts by binding to progesterone receptors in target tissues, including the endometrium, breast, and hypothalamus. In the endometrium, MPA induces secretory changes and opposes the proliferative effects of estrogen, thereby reducing the risk of endometrial hyperplasia. At the hypothalamic-pituitary level, MPA suppresses gonadotropin (LH and FSH) secretion, inhibiting ovulation when used in contraceptive doses. It also has mild androgenic and glucocorticoid activities, though these are clinically less significant.

Clinical Uses

Provera is approved for several indications, including:

1. Abnormal Uterine Bleeding (AUB): MPA is used to treat dysfunctional uterine bleeding, particularly when due to hormonal imbalances without underlying pathology. It stabilizes the endometrium, reduces heavy bleeding, and can be used cyclically or continuously.
   
   
2. Amenorrhea: In women with secondary amenorrhea and adequate endogenous estrogen, Provera can induce withdrawal bleeding, helping to restore menstrual cycles. It is also used as a diagnostic tool to assess estrogen status.
   
   
3. Endometriosis: By suppressing ovarian activity and inducing decidualization of endometrial implants, MPA can alleviate pain and reduce lesion size, though it is not first-line therapy due to side effects.
   
   
4. Contraception: Depo-Provera, the injectable form (150 mg IM every 3 months), is a highly effective long-acting reversible contraceptive. Oral Provera is not typically used for contraception in the US, but it has been used in other countries.
   
   
5. Hormone Replacement Therapy: In postmenopausal women with intact uteri, MPA is combined with estrogen to prevent endometrial hyperplasia caused by unopposed estrogen. This combination is used in cyclic or continuous regimens as part of HRT.
   
   
6. Endometrial Cancer: High-dose MPA is used as palliative therapy for advanced or recurrent endometrial cancer, especially hormone-sensitive tumors.
   
   
7. Other Uses: Off-label uses include treatment of hirsutism, polycystic ovary syndrome (PCOS) to regulate menses, and as part of gender-affirming therapy in transmasculine individuals.
   
   

Dosage and Administration

Oral Provera is available in 2.5 mg, 5 mg, and 10 mg tablets. Dosing varies by indication:

• AUB: 5-10 mg daily for 5-10 days starting at day 16 of cycle.
  
• Amenorrhea: 5-10 mg daily for 5-10 days.
  
• HRT: Typically 2.5-5 mg daily (continuous) or 5-10 mg for 12-14 days per month (cyclic).
  
• Endometrial cancer: 200-400 mg daily.
  
  

Depo-Provera injectable suspension (150 mg/mL) is given intramuscularly every 3 months for contraception.

Side Effects

Common side effects include irregular bleeding or spotting, weight gain, headache, breast tenderness, dizziness, abdominal bloating, nausea, and mood changes (including depression). Long-term use, especially with Depo-Provera, is associated with bone mineral density loss, which is generally reversible upon discontinuation. Other risks include thromboembolic events (though lower than with estrogen-progestin combinations), fluid retention, and glucose intolerance. Rare but serious side effects include anaphylaxis, hepatotoxicity, and exacerbation of migraine headaches.

Contraindications and Precautions

Absolute contraindications include known or suspected pregnancy, undiagnosed vaginal bleeding, active thromboembolic disease, history of stroke or MI, liver disease (severe), and known or suspected breast cancer. Relative contraindications include depression, migraine, asthma, cardiac or renal dysfunction, 50mcg (hospitaldechepo.com) and diabetes. Provera should be used with caution in women with risk factors for osteoporosis, especially those using long-term Depot-MPA.

Drug Interactions

MPA is primarily metabolized by CYP3A4. Inducers of CYP3A4 (e.g., rifampin, phenytoin, carbamazepine, St. John's wort) may reduce its efficacy. Conversely, CYP3A4 inhibitors (e.g., ketoconazole, grapefruit juice) may increase levels. Provera may also alter the metabolism of other drugs, such as warfarin (enhanced anticoagulation) and insulin (decreased glucose control).

Special Populations

• Pregnancy/Lactation: MPA is teratogenic in animal studies and should not be used during pregnancy. It is excreted in breast milk in small amounts, but use during lactation is generally considered safe at low doses.
  
• Pediatric: Use for non-contraceptive indications in adolescents is limited; bone density effects are a concern.
  
• Elderly: No specific studies, but caution due to comorbidities.
  
  

Current Role and Clinical Considerations

Provera remains a valuable tool in gynecologic practice. Its use in HRT has declined since the Women's Health Initiative (WHI) trials raised concerns about breast cancer and cardiovascular risks, but low-dose, short-term use is still common for symptom management. Depo-Provera remains a popular contraceptive choice due to its convenience and efficacy, though concerns about bone loss have led to recommendations for limited duration (less than 2 years unless other methods are contraindicated). The oral form is less common for contraception but continues to be used for cycle control and endometrial protection.

Emerging alternatives include newer progestins (e.g., drospirenone, desogestrel) with better side effect profiles and fewer metabolic effects. However, MPA's low cost, long history, and established efficacy keep it relevant, particularly in resource-limited settings.

Conclusion

Provera (medroxyprogesterone acetate) is a versatile progestin with applications spanning contraception, menstrual regulation, hormone replacement, and cancer therapy. Its safety and efficacy are well-documented, though healthcare providers must weigh benefits against risks, especially regarding bone density and metabolic effects. Individualized patient counseling and monitoring remain essential to optimize outcomes.